Labiotech.eu’s Post

Paul Hyslop, from ARKLEY BIOTEK LLC Indianapolis, details an ongoing specific research approach to identify, characterize, and validate physiologically relevant neuronal targets of #H2O2 in designing therapeutics for #neurodegenerative disease progression The societal impact of #dementia resulting from the major neurodegenerative diseases such as #Alzheimer’s presents a growing and significant unmet medical need. (1) Various cellular #metabolic and structural deficits, neuroinflammation, and oxidative stress are known to result in the progressive loss of vulnerable non-regenerative #neurons. (2) Find out more here: https://bit.ly/3SZPklr

Our #4 spot goes to the V-Bio Ventures feature on Muna Therapeutics which develops therapies for neurodegenerative diseases such as Alzheimer’s and Parkinson’s. Muna's approach has really caught our readers’ attention. They focus on microglia, which are involved in both clearing misfolded proteins as well as creating inflammatory responses, worsening pathology. "Our goal is to change the treatment paradigm for patients with diseases that affect memory and cognition, which form the essence of who we are as people." https://lnkd.in/g2ru33Ds #memoryloss #neurodegenerativediseases #alzheimers #parkinsons #multiplesclerosis #biotech #drugdiscovery

🧠 Exciting news from the EPND project (European Platform for Neurodegenerative Diseases (EPND))! Researchers from Amsterdam UMC and Universiteit Maastricht have made groundbreaking strides in understanding Alzheimer's disease. By analyzing cerebrospinal fluid samples, they've uncovered five distinct molecular subtypes of Alzheimer's. This discovery could revolutionize treatment development, as it suggests certain drugs may be more effective for specific patient groups. With over 140 drug targets being explored, this tailored approach could significantly enhance treatment outcomes. EPND's collaborative effort, supported by Lygature, underscores the importance of sharing data and samples in advancing neurodegenerative research. Read more about this promising breakthrough and the future steps in this article: https://lnkd.in/ebeFufc9   #EPND #AlzheimersResearch #Neuroscience

We have had a fantastic weekend here at 10th Congress of the European Academy of Neurology in Helsinki and are looking forward to what this Monday will bring! #ean2024 is nicely organized and we have learned a lot through interesting presentations and sessions. Very rewarding has been to meet with so many competent, curious Neurologists, Researchers, Students and Industry Peers visiting our booth at E02 sharing their knowledge and interacting in very fruitful conversations. If you yet haven’t visited us yet we are here today and tomorrow Tuesday. Through Wieslab Diagnostic Services, specializing in Autoimmune and Neurology testing, we can assist with e.g. fast turnaround of e.g. #NfL #Encephalitis #CIDP #AutoimmuneNodopathy #MOG #pTAU181 #Aquaporin4 #Autoantibodies and #Neuroimmunology analyzes. For a full view of available analyzes through our specialized autoimmune lab in Malmö, Sweden, come by and have a look at our request forms. If you are working to develop new drugs to target e.g. the #ComplementSystem, Svar Life Science can assist you with functional and Biomarker ELISA kits to study the effects on the Complement System. We also provide market leading #iLite gene reporter cells for those looking for #PotencyAssays #NAbAssays and #MoAassay (#ADCC, #ADCP, #CDC). Finally our #CROService can assist with #BioanalysisServices from exploratory phase through clinical trials up to GMP-release. #EAN2024 #Wieslab #SvarLifeScience #NF155 #NF186 #CNTN1 #CASPR1 #IgGSubclass

#neurodegenerativedisorders #Tau #synapses #cells #therapy Therapies for Tau-associated neurodegenerative disorders: targeting molecules, synapses, and cells https://lnkd.in/g-KWE4q3 University of Cambridge Advances in experimental and computational technologies continue to grow rapidly to provide novel avenues for the treatment of neurodegenerative disorders. Despite this, there remain only a handful of drugs that have shown success in late-stage clinical trials for Tau-associated neurodegenerative disorders. The most commonly prescribed treatments are symptomatic treatments such as cholinesterase inhibitors and N-methyl-D-aspartate receptor blockers that were approved for use in Alzheimer’s disease. This mini-review will highlight five key avenues of academic and industrial research for identifying therapeutic strategies to treat Tau-associated neurodegenerative disorders. These avenues include investigating (1) the broad class of chemicals termed “small molecules”; (2) adaptive immunity through both passive and active antibody treatments; (3) innate immunity with an emphasis on microglial modulation; (4) synaptic compartments with the view that Tau-associated neurodegenerative disorders are synaptopathies. Although this mini-review will focus on Alzheimer’s disease due to its prevalence, it will also argue the need to target other tauopathies, as through understanding Alzheimer’s disease as a Tau-associated neurodegenerative disorder, we may be able to generalize treatment options. For this reason, added detail linking back specifically to Tau protein as a direct therapeutic target will be added to each topic.

Dear Linked team, I am so proud to share that the novel research article by my amazing ISEST team was published today. It is entitled: "Novel therapeutical approaches based on neurobiological and genetic strategies for diabetic polyneuropathy" – A review in Diabetes & Metabolic Syndrome: Clinical Research & Reviews Journal. Big congratulations to my hard-working team, and especially Emina K. Sher MPharm, PhD, who was the heart of this project. 🎉🌸 • Journal: Diabetes & Metabolic Syndrome: Clinical Research & Reviews • *Journal Impact Factor: 10* • H-Index: 71 • *Journal Rating: Q1* • Publisher: Elsevier – Netherlands • Publication Date: 5 November 2023 Neuropathy is among the most often reported consequences of diabetes and the biggest cause of morbidity and mortality in people suffering from this life-long disease. There are various traditional drugs and non-pharmacological methods used to treat this health condition. However, the research in the area of pathogenic-oriented drugs in the treatment of DN showed no recent breakthroughs, mostly due to the limited evidence about their effectiveness and safety obtained through clinical trials. Consequently, there is an urgent demand for the development of novel therapeutic options for diabetic neuropathy. Some of the latest novel diagnostic methods for diagnosing diabetic neuropathy are discussed as well as the new therapeutic approaches, such as the fusion of neuronal cells with stem cells, targeting gene delivery and novel drugs. #diabetes #neuropathy #neurology #imunology #stemcells #inflammation #geneticengineering Feel free to read, share and recommend our new article via provided link: https://lnkd.in/efQT2dPM

#transcript Alon Ben-Noon, CEO and board member of NeuroSense Therapeutics, is taking a unique approach to treating neurodegenerative diseases by targeting core pathologies and combining molecules to address various mechanisms. NeuroSense has seen positive clinical trial results for ALS using their lead compound PrimeC, which showed a reduction in disease progression. Research indicates the potential for this approach to be applied to other neurodegenerative diseases like Alzheimer's and Parkinson's.   #NeuroSense #ALS #Parkinsons #Alzheimers #NeurodegenerativeDiseases NeuroSense-TX.com https://lnkd.in/gHxWFNkN

Alzheimer's Disease: Why Tau Holds the Key to New Therapies Recent breakthroughs have reignited the focus on Tau as a prime therapeutic target in Alzheimer's Disease (AD). While amyloid plaques have dominated research for decades, Tau pathology's extensive presence and correlation with cognitive decline demand closer attention. Here's why Tau is a compelling target for future AD therapeutics: Ubiquitous Pathology: Tau tangles, composed of hyperphosphorylated Tau protein, are present in a vast majority of AD cases, unlike the variable amyloid plaque burden. Early Intervention Potential: Tau pathology often precedes significant neuronal loss and clinical symptoms, offering a window for therapeutic intervention before irreversible damage occurs. Diverse Therapeutic Strategies: The multifaceted nature of Tau pathology presents a rich landscape for drug development. Approaches range from inhibiting Tau aggregation to promoting its clearance and microtubule stabilization. Stay tuned for future posts delving into the latest scientific advancements in Tau-targeted therapies! Let's foster a dynamic discussion about Tau's role in AD and its potential to unlock new avenues for treatment. #Alzheimers #Tau #NeurodegenerativeDisease #Neuroplasticity #Microtubules #ADResearch P.S. Are you investigating a therapy for AD? At IAG, IMAGE ANALYSIS GROUP we understand the complexity of Tauopathies, Dementias, and other forms of neurodegeneration. Reach out to me or imaging.experts@ia-grp.com to see how our neuroscience expertise can boost your clinical trial plans through medical imaging.

Background: Parkinson disease (PD) is a prevalent neurodegenerative disorder affecting dopaminergic neurons in the substantia nigra (SN). Neuroinflammation has a vital role in PD pathophysiology. Objectives: This study assesses whether the neuroinflammatory molecular and signaling pathways could be associated with PD’s progression and clinical manifestations. Materials & Methods: PubMed, Web of Science, Embase, and Scopus databases were investigated from 2006 until December 2023 to find relevant studies. All observational studies written in English and reporting qualitative or quantitative information on the relationship between neuroinflammation and PD were included in this review. Results: Finally, 41 papers were involved in the systematic review. According to the involved studies, it is suggested that tumor necrosis factor-α, C-reactive protein, microsomal prostaglandin E synthase1, toll-like receptor-4 (TLR-4), CCL23, CCL25, TNF-receptor superfamily member 9, EV-derived cytokines, transforming growth factor alpha, vascular endothelial growth factor A, SH-SY5Y, TLR 2/4, miR-485-3p, leucine-rich repeat kinase 2, and α-synuclein may be upregulated in the PD patients. Also, the activity of astrocytes and microglial cells was reported to be increased in PD patients through different mechanisms.  Conclusion: This study demonstrated that the neurodegeneration in PD could be initiated by α-synuclein protein aggregation and the activation of astrocytes and microglial cells, which leads to neuroinflammation characterized by inflammatory responses in neurons. Finally, chronic neuroinflammation could be the cause of dopaminergic neuronal death in SN. The impact of both single and all factors involved in neuroinflammation was assessed to plan further studies in a particular pathway to intercept the onset of inflammatory pathways in favor of therapeutic purposes.    #CReactiveProtein #TumorNecrosisFactorα, #αSynuclein, #TollLikeReceptor2, #TLR9

Exciting news: Vanqua Bio is making strides in neurodegenerative disorder treatment, as its developmental candidate, VQ-101, is set to enter clinical trials in early 2024, targeting Parkinson's disease. The molecule activates glucocerebrosidase (GCase), crucial for lysosome function. GBA1 gene mutations, prevalent in Parkinson's patients, lead to reduced GCase activity, causing harmful protein accumulation in neurons. Preclinical studies show VQ-101's effectiveness in activating GCase, reducing substrates, and blocking protein accumulation. Vanqua also appointed key executives—Dr. Jesse Cedarbaum, MD, and Omer Siddiqui as CMO and CDO, respectively, and Dr. Rand Sutherland to the Board of Directors—to bolster its clinical evolution. The company aims to demonstrate safety and efficacy in human trials, contributing to a new era of hope for neurodegenerative disorder patients. For more information please find the link attached: https://lnkd.in/ernGakZY #neurology #neuroscience #parkinsonsdisease #clinicaltrials #biotech